UNDERSTANDING THE UTILITY VALUE OF PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA
Author(s)
Hadi M1, Swinburn P1, de Freitas HM1, Ito T2
1Mapi Group, London, UK, 2Janssen Health Economics & Market Access EMEA, High Wycombe, UK
OBJECTIVES:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PRM175
Topic
Methodological & Statistical Research
Topic Subcategory
PRO & Related Methods
Disease
Oncology
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now